# Potassium Citrate

```text
DRUG INFORMATION

  ADULT
    - Objective: To restore normal urinary citrate (greater than 320 mg/day and as close
      to the normal mean of 640 mg/day as possible), and to increase urinary pH to a
      level of 6.0 to 7.0.
      Source: US FDA label for potassium citrate (Potassium Citrate), section 'dosage
      and administration', retrieved 2026-08-29
    - The objective of treatment with potassium citrate extended-release tablets is to
      provide potassium citrate extended-release tablets in sufficient dosage to restore
      normal urinary citrate (greater than 320 mg/day and as close to the normal mean of
      640 mg/day as possible), and to increase urinary pH to a level of 6.0 or 7.0.
      Source: US FDA label for potassium citrate (Potassium Citrate), section 'dosage
      and administration', retrieved 2026-08-29
    - Treatment should be discontinued if there is hyperkalemia, a significant rise in
      serum creatinine or a significant fall in blood hematocrit or hemoglobin. 2.2
      Severe Hypocitraturia In patients with severe hypocitraturia (urinary citrate <
      150 mg/day), therapy should be initiated at a dosage of 60 mEq/day (30 mEq two
      times/day or 20 mEq three times/day with meals or within 30 minutes after meals or
      bedtime snack).
      Source: US FDA label for potassium citrate (Potassium Citrate), section 'dosage
      and administration', retrieved 2026-08-29

  CHILD
    - Safety and effectiveness in children have not been established.
      Source: US FDA label for potassium citrate (Potassium Citrate), section 'pediatric
      use', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for potassium citrate (Potassium
      Citrate), retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for potassium citrate (Potassium
      Citrate), retrieved 2026-08-29

  PREGNANCY
    - Animal reproduction studies have not been conducted.
      Source: US FDA label for potassium citrate (Potassium Citrate), section
      'pregnancy', retrieved 2026-08-29
    - It is also not known whether potassium citrate extended-release tablets can cause
      fetal harm when administered to a pregnant woman or can affect reproduction
      capacity.
      Source: US FDA label for potassium citrate (Potassium Citrate), section
      'pregnancy', retrieved 2026-08-29
    - Potassium citrate extended-release tablets should be given to a pregnant woman
      only if clearly needed.
      Source: US FDA label for potassium citrate (Potassium Citrate), section
      'pregnancy', retrieved 2026-08-29

  BREASTFEEDING
    - The normal potassium ion content of human milk is about 13 mEq/L.
      Source: US FDA label for potassium citrate (Potassium Citrate), section 'nursing
      mothers', retrieved 2026-08-29
    - It is not known if potassium citrate extended-release tablets has an effect on
      this content.
      Source: US FDA label for potassium citrate (Potassium Citrate), section 'nursing
      mothers', retrieved 2026-08-29
    - Potassium citrate extended-release tablets should be given to a woman who is
      breast feeding only if clearly needed.
      Source: US FDA label for potassium citrate (Potassium Citrate), section 'nursing
      mothers', retrieved 2026-08-29
```

---

Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement.

[Privacy policy](/privacy)